Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine

Stone, Peter H.; Gratsiansky, N.A.; Blokhin, A.; Huang, I‐Zu; Meng, Lingfei; Investigators, Erica

doi:10.1016/j.jacc.2006.05.044

Cited by 328 publications

(241 citation statements)

References 26 publications

Supporting

Mentioning

223

Contrasting

Unclassified

Order By: Relevance

“…This study also claims that better antianginal effects were observed with ranolazine in patients with increased frequency of angina episodes [26]. Similarly the TERISA trial showed significant reduction in angina frequency from 6.6 to 3.8 per wk after 8 wk of treatment with ranolazine 1000 mg BD compared to placebo group [27].…”

Section: Discussionmentioning

confidence: 71%

Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial

Selvarajan

Dkhar

Pillai

et al. 2015

JCDR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 71%

Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial

Selvarajan

Dkhar

Pillai

et al. 2015

JCDR

View full text Add to dashboard Cite

“…Its anti‐ischemic effects have been demonstrated by several clinical trials 3, 4, 5, 6. Additionally, it exerts modulatory effects on ion channels that have been similarly observed after chronic amiodarone use, such as reductions in I Kr , I Ks , late I Na , and I Ca 7.…”

Section: Introductionmentioning

confidence: 94%

Impact of ranolazine on ventricular arrhythmias – A systematic review

Bazoukis

Tse

Letsas

et al. 2018

Journal of Arrhythmia

View full text Add to dashboard Cite

Ranolazine is a new medication for the treatment of refractory angina. However, except its anti‐anginal properties, it has been found to act as an anti‐arrhythmic. The aim of our systematic review is to present the existing data about the impact of ranolazine in ventricular arrhythmias. We searched MEDLINE and Cochrane databases as well clinicaltrials.gov until September 1, 2017 to find all studies (clinical trials, observational studies, case reports/series) reported data about the impact of ranolazine in ventricular arrhythmias. Our search revealed 14 studies (3 clinical trials, 2 observational studies, 8 case reports, 1 case series). These data reported a beneficial impact of ranolazine in ventricular tachycardia/fibrillation, premature ventricular beats, and ICD interventions in different clinical settings. The existing data highlight the anti‐arrhythmic properties of ranolazine in ventricular arrhythmias.

show abstract

“…ERICA çalışmasında ise maksimal amlodipin (günde 10 mg oral) tedavisine günde iki defa 1000 mg ranolazin eklenmesinin ek yarar getirip getirmediği incelenmiştir 54 . Ranolazinin, angina sıklığını ve nitrat tüketimini anlamlı derecede azalttığı, kadın ve erkek hastalarda uzun etkili nitrat alan ve almayanlarda, 65 yas üzeri ya da altındaki hastalarda aynı derecede etkili olduğu görülmüştür.…”

Section: Ranolozinunclassified

Kararlı Koroner Arter Hastalığında Güncel İlaç Tedavisi

Tekin¹,

Tekin²

2015

Arşiv Kaynak Tarama Dergisi

View full text Add to dashboard Cite

Coronary artery disease is the leading cause of death in the world. Despite the increasing success of conventional medical therapies and the continued development and improvement of percutaneous coronary intervention, a significant number of patients with ischemic heart disease and angina pectoris cannot be successfully managed. There are two major purposes in the treatment of stable angina. The first is to prevent myocardial infarction and death and thereby, increase the quantity of life. The second is to reduce symptoms of angina and the frequency and severity of ischemia, which should improve the quality of life. Antiischemic agents, including beta-blockers, nitrates and calcium channel blockers, remain the mainstay in the prevention of angina. Also new pharmacological options for refractory angina, metabolic agents, and vasodilator therapies are adding to the armamentarium to prevent and treat angina. This review will summarize current recommended pharmacological approaches of stable coronary artery disease, with a focus on novel therapies.

show abstract

Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine

Abstract: Ranolazine significantly reduced frequency of angina and nitroglycerin consumption compared with placebo and was well tolerated. (The ERICA [Efficacy of Ranolazine In Chronic Angina] Trial; http://clinicaltrials.gov; NCT00091429).

Cited by 328 publications

References 26 publications

Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial

Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial

Impact of ranolazine on ventricular arrhythmias – A systematic review

Kararlı Koroner Arter Hastalığında Güncel İlaç Tedavisi

Contact Info

Product

Resources

About